Post by BioThrust
4,932 followers
šŗ š š¶ššš²š± š¼ššæ š¶š£š¦š šš²šÆš¶š»š®šæ? š¬š¼š š°š®š» š»š¼š šš®šš°šµ ššµš² š³šš¹š¹ šæš²š°š¼šæš±š¶š»š“. In this session, Patrick Bongartz and Marco Oliveira introduce BioThrust, explain the scientific principles of our ComfyCell bioreactor technology, and present a detailed review of our record-setting iPSC expansion proof-of-concept experiments. š§š²š°šµš»š¶š°š®š¹ š¦ššŗšŗš®šæš:  ⢠Up to 10x the gas transfer (O2 in, CO2 out) of other bioreactors  ⢠No deadzones in the bioreactor, smooth and homogeneous flow  ⢠Flexible design, compatible with a wide range of analytics and perfusion šš¶š¼š¹š¼š“š¶š°š®š¹ š¦ššŗšŗš®šæš:  ⢠Removed all gas transfer limits from fed-batch iPSC expansion - now purely nutrient limited  ⢠World record iPSC expansion at 300mL and scale up to 2L: Up to 44 million iPSCs per mL  ⢠Controlled aggregate sizes and full pluripotency maintained A big thank you to everyone who joined our European and US sessions. We were genuinely impressed by the level of interest in this first webinar series. It highlights a shared reality across the field: efficient iPSC manufacturing remains an unsolved challenge, and the need for scalable, commercially viable solutions is more urgent than ever to advance cell therapies and improve patient outcomes. š š šŖš®šš°šµ ššµš² šæš²š°š¼šæš±š¶š»š“ šµš²šæš²: https://lnkd.in/e2xaJAbz